Colorectal adenocarcinoma

1. Introduction and Definition

Colorectal adenocarcinoma (CRC) is a malignant neoplasm arising from the glandular epithelial cells lining the colon and rectum. It represents the vast majority—approximately 95% to 98%—of all colorectal malignancies. Other rare histological subtypes include neuroendocrine tumors, gastrointestinal stromal tumors (GISTs), lymphomas, and squamous cell carcinomas, but the term “colorectal cancer” is clinically synonymous with adenocarcinoma in the overwhelming majority of cases.

CRC is a major global health burden. According to GLOBOCAN 2020 estimates, it is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. The disease typically develops through a defined molecular pathway progressing from normal mucosa to adenomatous polyp (adenoma) and finally to invasive carcinoma—a sequence known as the adenoma-carcinoma sequence. This protracted natural history, often spanning 10 to 15 years, provides a unique window of opportunity for prevention and early detection through screening.

2. Epidemiology and Risk Factors

Understanding the distribution and determinants of CRC is fundamental for risk stratification and screening guidelines.

Incidence and Demographics

• Age: Incidence rises sharply after age 50. However, a concerning trend of early-onset CRC (diagnosis < 50 years) has been documented globally since the mid-1990s, increasing by 1–2% annually.
• Sex: Slightly higher incidence in males compared to females (ratio ~1.2:1 to 1.5:1). Rectal cancer shows a stronger male predominance.
• Geography: Highest rates in Australia/New Zealand, Europe, and North America; lowest in Africa and South-Central Asia. Migration studies confirm environmental/lifestyle dominance over genetics.

Modifiable Risk Factors (Lifestyle & Environment)

Non-Modifiable Risk Factors

• Age: The single strongest risk factor.
• Personal History: Previous CRC or high-risk adenomas (villous histology, high-grade dysplasia, size ≥10mm, ≥3 adenomas).
• Inflammatory Bowel Disease (IBD): Ulcerative Colitis (UC) and Crohn’s colitis. Risk depends on extent (pancolitis > left-sided > proctitis), duration (>8–10 years), and severity of inflammation. Primary Sclerosing Cholangitis (PSC) further elevates risk.
• Family History:
• One first-degree relative (FDR) diagnosed <60 years, or two FDRs at any age → 2x to 4x risk.
• Familial clustering accounts for ~25% of cases; defined hereditary syndromes account for ~5–10%.

Hereditary Syndromes (Major Types)

Clinical Pearl: All patients diagnosed with CRC < 70 years (or < 50 years per some guidelines) should undergo universal tumor testing for Mismatch Repair (MMR) deficiency (IHC) or Microsatellite Instability (MSI-PCR)** to screen for Lynch Syndrome, regardless of family history.

3. Pathogenesis and Molecular Biology

CRC is not a single disease but a collection of molecular subtypes. The “Vogelgram” (Fearon & Vogelstein, 1990) describes the classic Adenoma-Carcinoma Sequence (Chromosomal Instability – CIN Pathway), but alternative pathways exist.

Major Molecular Pathways

A. Chromosomal Instability (CIN) Pathway (~65–70% of sporadic CRC)

• Hallmark: Gross chromosomal abnormalities (aneuploidy, loss of heterozygosity – LOH).
• Sequence:

1. APC mutation (Gatekeeper): Loss of β-catenin degradation → constitutive Wnt signaling → cellular proliferation. Early event (adenoma initiation).
2. KRAS mutation (Oncogene): Constitutive MAPK/PI3K signaling → growth autonomy. Intermediate event (adenoma growth).
3. TP53 mutation (Guardian): Loss of apoptosis/DNA repair checkpoint. Late event (transition to carcinoma).
4. 18q LOH (SMAD4, DCC): TGF-β resistance.

• Location: Predominantly left-sided / rectal.
• Precursor: Conventional tubular/tubulovillous/villous adenoma.

B. Microsatellite Instability (MSI) Pathway (~15% sporadic; ~100% Lynch)

• Hallmark: Defective DNA Mismatch Repair (dMMR) → accumulation of errors in repetitive DNA sequences (microsatellites).
• Cause:
• Sporadic: Epigenetic silencing of MLH1 promoter hypermethylation (associated with CIMP-high, BRAF V600E mutation, older females, right-sided).
• Hereditary: Germline mutation in MLH1, MSH2, MSH6, PMS2 (Lynch Syndrome).
• Precursor: Sessile Serrated Lesions (SSLs) / Traditional Serrated Adenomas (TSAs).
• Features: Right-sided predominance, mucinous/histology, poor differentiation, Tumor-Infiltrating Lymphocytes (TILs), Crohn-like reaction, better stage-for-stage prognosis, predictive resistance to 5-FU monotherapy (adjuvant), predictive response to Immune Checkpoint Inhibitors (ICIs).

C. CpG Island Methylator Phenotype (CIMP) Pathway

• Hallmark: Genome-wide promoter hypermethylation silencing tumor suppressor genes (MLH1, CDKN2A/p16, MGMT).
• Subtypes: CIMP-High (overlaps MSI sporadic), CIMP-Low (overlaps CIN, KRAS mutant).
• Association: BRAF V600E mutation, right-sided, female, older age.

D. Serrated Pathway

• Describes the morphological precursor sequence: Hyperplastic Polyp (HP) → Sessile Serrated Lesion (SSL) → Dysplasia → Carcinoma.
• Driven by BRAF mutation → CIMP-High → MLH1 methylation → MSI-H Cancer (Sporadic).
• KRAS mutant SSLs → CIMP-Low → MSS Cancer.

Consensus Molecular Subtypes (CMS) – Functional Classification

Transcriptome-based classification (Guinney et al., 2015) provides prognostic and predictive value beyond histology.

4. How Does It Look? (Gross and Microscopic Pathology)

This section details the macroscopic appearance during endoscopy/surgery and the microscopic diagnostic criteria used by pathologists.

Gross (Macroscopic) Morphology

The gross appearance correlates with tumor location and growth pattern (Borrmann classification for advanced cancers).

A. Polypoid / Fungating (Exophytic) – “Cauliflower-like”

• Appearance: Frond-like, papillary projections growing into the lumen. Often ulcerated on the surface.
• Location: Typical of right-sided (cecum, ascending colon) tumors where the lumen is wide and stool is liquid.
• Symptoms: Often occult bleeding (iron deficiency anemia), rarely obstruction due to large lumen.
• Endoscopic View: Large, friable mass with irregular surface, easy bleeding on contact.

B. Ulcerative / Infiltrative (Endophytic) – “Napkin Ring” / “Apple Core”

• Appearance: Circumferential growth infiltrating the bowel wall circumferentially, causing concentric narrowing. Central ulceration with raised, indurated (hard) edges.
• Location: Typical of left-sided (descending, sigmoid) and rectal tumors where the lumen is narrower and stool is solid.
• Symptoms: Obstruction (colicky pain, distension), tenesmus, hematochezia, change in caliber of stool.
• Endoscopic View: Tight stricture, often difficult/impossible to pass scope. “Shouldering” of edges.

C. Annular (Constricting) / “Carcinoma en cuirasse” (Leather Bottle)

• Appearance: Diffuse infiltration of the wall without a discrete mass, leading to rigid, thickened, non-distensible bowel segment.
• Location: Rectum, sometimes stomach (linitis plastica), rarely colon.
• Significance: Poor prognosis, often advanced (T4b) at diagnosis.

D. Superficial Spreading / Laterally Spreading Tumors (LSTs)

• Appearance: Flat or minimally elevated lesions extending laterally along the mucosal surface (>10mm).
• Subtypes: LST-G (Granular) vs. LST-NG (Non-granular). LST-NG pseudo-depressed type has high risk of deep submucosal invasion (SMIC).
• Significance: Precursors (SSLs, large tubular adenomas) or early cancers amenable to Endoscopic Submucosal Dissection (ESD).

E. Borrmann Classification (Advanced Gastric/Colorectal)

Microscopic (Histopathological) Features

Diagnosis requires invasion through the muscularis mucosae into the submucosa.

A. Architectural Patterns (WHO Grading)

• Well Differentiated (Grade 1 / Low Grade): >95% gland formation. Glands are regular, tubular, lined by polarized columnar cells with basal nuclei. Minimal mitosis. Resembles normal crypts.
• Moderately Differentiated (Grade 2 / Low Grade): 50–95% gland formation. Glands show variability in size/shape (branching, budding), some cribriforming. Nuclei stratified, hyperchromatic, prominent nucleoli. Mitoses frequent. Most common grade.
• Poorly Differentiated (Grade 3 / High Grade): <50% gland formation. Solid sheets, cords, or single cells. Marked nuclear pleomorphism, high mitotic rate (including atypical forms), necrosis. Signet ring cells (mucin vacuole displacing nucleus) if >50% → Signet Ring Cell Carcinoma (distinct aggressive entity).
• Undifferentiated (Grade 4): No gland formation. Sheets of cells. Requires IHC (CK20, CDX2, SATB2) to confirm colorectal origin.

Critical Concept: Tumor Budding. Defined as single cells or small clusters (<5 cells) at the invasive front. High-grade budding (≥10 buds/0.785mm² at 20x) is an independent adverse prognostic factor (lymph node metastasis, recurrence, worse survival) and upgrades risk in early CRC (pT1).

B. Histological Variants (WHO Recognized)

C. Immunohistochemistry (IHC) Panel (Standard Diagnostic Workup)

5. Symptoms and Clinical Presentation

Symptoms depend on tumor location, size, growth pattern, and presence of complications (obstruction, perforation, metastasis). Early CRC is frequently asymptomatic, underscoring the necessity of screening.

Local Symptoms (Primary Tumor Effects)

A. Right-Sided Colon (Cecum, Ascending, Hepatic Flexure, Transverse)

• Lumen: Wide diameter; liquid stool.
• Presentation: Insidious, chronic.
• Key Symptom: Iron Deficiency Anemia (IDA). Chronic occult blood loss > dietary absorption. Presents as fatigue, exertional dyspnea, pallor, restless legs, pica. IDA in a male or postmenopausal female = CRC until proven otherwise.
• Abdominal Pain: Vague, dull, right lower quadrant (RLQ) or periumbilical. Rarely obstructive until late.
• Palpable Mass: Right lower quadrant mass (cecal carcinoma) in ~20-30% at diagnosis.
• Weight Loss / Cachexia: Systemic cytokine release (TNF-α, IL-1, IL-6) → hypermetabolism/anorexia.

B. Left-Sided Colon (Splenic Flexure, Descending, Sigmoid)

• Lumen: Narrower; solid stool.
• Presentation: Earlier, mechanical.
• Hematochezia: Bright red or dark red blood mixed with stool (vs. hemorrhoids: blood on paper/toilet water, coating stool). Most common presenting symptom.
• Change in Bowel Habits: Constipation (progressive), alternating diarrhea/constipation, tenesmus (urgency with little stool – rectal/sigmoid), narrowing of stool caliber (“pencil-thin” stools).
• Abdominal Pain: Crampy, colicky, left lower quadrant (LLQ). Sign of impending obstruction.
• Large Bowel Obstruction (LBO): Acute abdominal distension, vomiting, absolute constipation/obstipation, high-pitched bowel sounds. Surgical emergency. Sigmoid volvulus mimic.

C. Rectal Cancer (Specific Syndromes)

• Tenesmus: Persistent, painful urge to defecate with minimal output. Highly specific for rectal lesion.
• Hematochezia: Bright red blood, often separate from stool or coating it.
• Incomplete Evacuation: Sensation of residual stool.
• Perineal/Sacral Pain: Late sign → invasion of presacral fascia / sacral plexus (S2-S4) → Tumor fixed on DRE, urinary retention, sexual dysfunction, sciatica. Contraindicates sphincter preservation (requires APR/exenteration).
• Mucous Discharge: Profuse mucus production (villous adenoma or mucinous adenocarcinoma).

Systemic / Constitutional Symptoms

• Unintentional Weight Loss: >5% body weight in 6 months. Poor prognostic sign.
• Anorexia / Early Satiety.
• Fatigue: Multifactorial (anemia, cytokines, metabolic derangement).
• Paraneoplastic Syndromes: Rare (e.g., DVT/Trousseau’s syndrome, dermatomyositis, acanthosis nigricans).

Symptoms of Metastatic Disease (Stage IV)

• Liver (Most common site – 70% of mets):
• Often asymptomatic initially.
• RUQ pain, hepatomegaly, jaundice (late, biliary obstruction), ascites.
• Liver function tests: Isolated ↑ALP/GGT (cholestatic pattern) → suspicious.
• Lungs (20%):
• Cough, dyspnea, hemoptysis, pleural effusion.
• Peritoneum (Peritoneal Carcinomatosis):
• Ascites (malignant), abdominal distension, bowel obstruction (serosal implants), “omental caking” on imaging.
• Bone / Brain: Bone pain, fractures, neurological deficits (rare as first site, more common in rectal/lung mets pathway).
• Ovarian (Krukenberg Tumor): Bilateral ovarian masses (signet ring histology common), often mistaken for primary ovarian cancer.

Emergency Presentations (Red Flags)

Clinical Decision Rule: “Alarm Symptoms” Warranting Urgent Colonoscopy (NICE / ESGE Guidelines): Age ≥ 50 (or ≥ 45 per newer US guidelines) with Rectal Bleeding + Change in Bowel Habit (to looser/increased frequency) persisting > 4-6 weeks. Age ≥ 60 with Rectal Bleeding alone (no anal symptoms). Iron Deficiency Anemia (Male / Postmenopausal Female) – Urgent Upper & Lower GI Endoscopy. Palpable Abdominal / Rectal Mass. Unexplained Weight Loss + Abdominal Pain. Note: Isolated rectal bleeding in young patients (<50) without risk factors is often benign (hemorrhoids/fissure) but requires clinical judgment.

6. Diagnosis and Staging Workup

A structured diagnostic pathway is essential for treatment planning.

Primary Tumor Diagnosis

1. Colonoscopy (Gold Standard):

• Visualization of entire mucosa to cecum/terminal ileum.
• Biopsy: Multiple (≥ 4-6) forceps biopsies from center and edge.
• Tattooing: Endoscopic tattoo (India ink/Spot) proximal to lesion if surgery planned (localization for laparoscopic resection).
• Polypectomy: If malignant polyp (pedunculated/sessile) removed en bloc with clear margins → potential curative endoscopic treatment (see pT1 management).

1. CT Colonography (Virtual Colonoscopy): Alternative if incomplete colonoscopy / frailty. Requires bowel prep. No biopsy capability. Radiation exposure.
2. Flexible Sigmoidoscopy: Limited to rectosigmoid. Used in screening programs (e.g., UK Bowel Scope) or acute bleeding workup.

Staging Investigations (TNM – AJCC 8th Edition / UICC)

TNM Staging Summary (AJCC 8th Ed.) – Simplified

• T1: Submucosa invasion.
• T2: Muscularis propria invasion.
• T3: Through muscularis propria into subserosa/pericolic fat.
• T4a: Perforation of visceral peritoneum.
• T4b: Direct invasion of adjacent organs/structures.
• N1: 1-3 regional nodes. N1c: Tumor deposits (TDs) in subserosa/mesentery without nodal metastasis.
• N2: ≥4 regional nodes.

7. Management Principles by Stage

Treatment is multidisciplinary (MDT discussion mandatory for all non-early/non-metastatic complex cases).

Stage 0 & I (Early) / Malignant Polyp (pT1)

• Polypectomy (Endoscopic Resection – EMR/ESD):
• Curative if: En bloc resection (preferred ESD for >20mm / non-granular), R0 (negative deep & lateral margins), Well/Moderate differentiation, No Lymphovascular Invasion (LVI-), No Perineural Invasion (PNI-), Low Tumor Budding (Bd1/2), Sm1 invasion (<1000µm or <Haggitt Level 4).
• Surgery Indicated (Completion Colectomy): Positive margins, Poor differentiation, LVI+, PNI+, High Budding (Bd3), Sm2/3 deep invasion, Fragmented resection preventing accurate assessment.
• Surgical Resection (Segmental Colectomy + Lymphadenectomy): Standard for T2, or T1 with high-risk features. Laparoscopic approach standard (non-inferior oncologic outcomes, faster recovery).

Stage II (Node Negative) – The Adjuvant Chemotherapy Dilemma

• Standard: Surgery alone (Colectomy with adequate lymphadenectomy ≥12 nodes).
• Adjuvant Chemotherapy (Oxaliplatin-based: CAPOX/FOLFOX) Considered for High-Risk Features:
• T4 stage (IIB/IIC).
• Inadequate Lymph Node Harvest (<12 nodes).
• Lymphovascular Invasion (LVI+).
• Perineural Invasion (PNI+).
• High Tumor Budding (Bd3).
• Obstruction / Perforation at presentation.
• Poor Differentiation (Grade 3/4) / Mucinous / Signet Ring histology.
• Pre-op CEA Elevated.
• dMMR/MSI-H Status: STRONG PREDICTIVE MARKER. Stage II dMMR/MSI-H tumors have excellent prognosis with surgery alone and DO NOT BENEFIT (may be harmed) by 5-FU/Oxaliplatin adjuvant therapy. Guidelines recommend NO adjuvant chemo for Stage II dMMR/MSI-H.

Stage III (Node Positive) – Adjuvant Chemotherapy Standard

• Surgery First (Upfront Resection): R0 resection with Total Mesorectal Excision (TME) for rectum / Complete Mesocolic Excision (CME) for colon. Minimum 12 nodes.
• Adjuvant Chemotherapy: CAPOX (Capecitabine + Oxaliplatin) x 3 months (4 cycles) OR FOLFOX x 6 months (12 cycles).
• IDEA Collaboration Result: 3 months CAPOX non-inferior to 6 months for low-risk Stage III (T1-3 N1), with significantly less neuropathy. 6 months preferred for High-Risk (T4 and/or N2).
• dMMR/MSI-H in Stage III: Prognosis better than pMMR. Benefit from 5-FU debated (historically resistance), but Oxaliplatin adds benefit. Current standard: Treat per risk stratification (CAPOX 3mo often used), but discuss lack of 5-FU benefit.

Rectal Cancer Specifics – The “Total Neoadjuvant Therapy” (TNT) Era

• Locally Advanced (cT3-T4 / cN+ / CRM threatened on MRI): Neoadjuvant Therapy is Standard.
• Paradigm Shift (PROSPECT, RAPIDO, OPRA, PRODIGE trials):
• TNT (Total Neoadjuvant Therapy): Systemic Chemo (FOLFOX/CAPOX) ± Radiotherapy (Short-course RT 5x5Gy or Long-course CRT 50.4Gy/28fx + 5-FU/Cape) BEFORE Surgery.
• Benefits: Higher compliance, better systemic control, higher pathologic complete response (pCR) rates, Organ Preservation (Watch & Wait) strategy for clinical Complete Responders (cCR).
• Short-Course RT (5x5Gy) + Delayed Surgery (4-8 wks) or Consolidation Chemo: Standard for many (Stockholm III, RAPIDO).
• Organ Preservation (Watch & Wait): For patients achieving cCR (Endoscopy: white scar/flat mucosa; MRI: fibrosis/no mass; DRE: normal) after TNT. Strict surveillance (q3-4mo x 2yrs, then q6mo). Salvage surgery (TME/APR) if local regrowth (~25-30% at 2-3 yrs). Preserves sphincter/quality of life.
• Early Rectal (cT1-2 N0): Local excision (TEM/TAMIS) or Upfront TME (if high risk features on ERUS/MRI).

Stage IV (Metastatic) – Chronic Disease Management

• Goal: Prolong survival, maintain Quality of Life (QoL), convert unresectable → resectable.
• Resectable Oligometastatic Disease (Liver ± Lung):
• Perioperative Chemotherapy: FOLFOXIRI + Bevacizumab (high response) or FOLFOX/CAPOX ± Bevacizumab (standard). Surgery (Liver Resection ± Portal Vein Embolization / Ablation / Lung Resection). Curative Intent possible (5-yr OS 40-50% post-resection).
• Unresectable / Widespread Disease (Palliative Systemic Therapy):
• Molecular Stratification is Mandatory:
• RAS/BRAF WT (Left-sided): FOLFOXIRI + Bevacizumab (aggressive, high response/resection conversion) OR FOLFOX/CAPOX + Anti-EGFR (Cetuximab/Panitumumab) (Superior OS in Left-sided WT per FIRE-3, CALGB 80405). Anti-EGFR contraindicated if RAS/RAF mut.
• RAS/BRAF WT (Right-sided): Anti-VEGF (Bevacizumab) + Chemo backbone preferred. Anti-EGFR detrimental in Right-sided.
• BRAF V600E Mutant: Triplet: Encorafenib (BRAFi) + Cetuximab (EGFRi) ± Binimetinib (MEKi) + Chemo? Standard 1st line: FOLFOXIRI + Bevacizumab OR Encorafenib + Cetuximab (+/- Binimetinib) (BEACON regimen approved 2nd/3rd line, moving to 1st line). Poor prognosis.
• MSI-H/dMMR (Any Stage IV): Immune Checkpoint Inhibitors (Pembrolizumab / Nivolumab ± Ipilimumab) – 1ST LINE STANDARD. High response rates (40-50%), durable responses. Avoid Chemo if possible.
• HER2 Amplified (RAS WT): Trastuzumab + Tucatinib / Lapatinib / Pertuzumab (2nd line+).
• NTRK Fusion: Larotrectinib / Entrectinib (Tumor agnostic approval).
• Maintenance Therapy: After 4-6 months induction (e.g., FOLFOX + Bev) → Capecitabine + Bevacizumab or Bevacizumab alone until progression/toxicity. Improves QoL.
• Local Ablative Therapies: SBRT (Stereotactic Body RT) for oligoprogression.

8. Post-Treatment Surveillance (Survivorship)

Goal: Detect curable recurrence (local, liver, lung) and metachronous neoplasia (new polyps/cancers).

Standard Surveillance Schedule (High Risk: Stage II/III; 5 Years Intensive)

Long-term Survivorship Issues

• LARS (Low Anterior Resection Syndrome): Cluster of bowel dysfunction (frequency, urgency, clustering, incontinence) after sphincter-saving surgery. Affects 50-90%. Management: Loperamide, pelvic floor rehab, irrigation (Transanal Irrigation), Sacral Nerve Stimulation.
• Stoma Care: Parastomal hernia, prolapse, retraction, skin excoriation. Stoma nurse specialist vital.
• Peripheral Neuropathy (Oxaliplatin-induced): Chronic, dose-limiting. Duloxetine (treatment), prevention (Ca/Mg infusions – controversial, cooling gloves/socks).
• Secondary Malignancies: Risk increased (treatment related: therapy-related MDS/AML post alkylators/topo II inhibitors; field effect: metachronous CRC).
• Psychosocial / Sexual Health / Financial Toxicity: Screening distress (NCCN Distress Thermometer). Referral to psycho-oncology, sexual health clinics, financial navigators.

9. Prevention and Screening

Primary Prevention (Lifestyle)

• Diet: High fiber (whole grains, vegetables, fruit), Calcium/Dairy, Limit Red/Processed Meat, Limit Alcohol.
• Physical Activity: ≥150 min moderate/week.
• Weight Control: Avoid central obesity.
• Smoking Cessation.
• Aspirin/NSAIDs: USPSTF recommends Low-dose Aspirin (81mg) for adults 50-59 with ≥10% 10-yr CVD risk (Grade B) / Individualized 60-69. Not recommended solely for CRC prevention in average risk. High dose/long term needed for adenoma reduction; bleeding risk significant.

Secondary Prevention (Screening) – Average Risk

• Starting Age: 45 years (USPSTF 2021, ACS 2018) / 50 years (Many EU/International guidelines – transitioning to 45).
• Stopping Age: 75 (Individualized 76-85).

References

Screening Algorithm (Simplified): 1. Patient Preference Discussion (Shared Decision Making). 2. Colonoscopy q10y OR Annual FIT are the two primary recommended strategies (USPSTF/ACG). 3. Positive Non-Invasive Test (FIT, mt-sDNA, CT Colonography) → Diagnostic Colonoscopy. 4. Surveillance Intervals Post-Polypectomy: Based on US Multi-Society Task Force (USMSTF) 2020 / ESGE 2022 Guidelines (Risk stratification: Low risk 1-2 small tubular adenomas → 7-10 yrs; High risk ≥3 adenomas, ≥10mm, Villous, HGD, SSL ≥10mm or dysplasia → 3 yrs; SPS → 1-3 yrs).

High-Risk Screening (Special Populations)

10. Emerging Trends and Future Directions

1. Liquid Biopsy (ctDNA – Circulating Tumor DNA):

• MRD (Minimal Residual Disease) Detection Post-Op (Stage II/III): DYNAMIC, GALAXY, COBRA trials. ctDNA+ → High recurrence risk → Adjuvant Chemo benefit. ctDNA- → Very low recurrence risk → Omission of Adjuvant Chemo safe (de-escalation). Becoming Standard of Care in many centers.
• Screening/Early Detection: Multi-cancer early detection (MCED) tests (Galleri, etc.) – Not yet recommended for average risk screening.

1. Neoadjuvant Therapy for Colon Cancer (FOxTROT, PRODIGE 44, NEOCOL):

• Short-course RT (5x5Gy) or Systemic Chemo (FOLFOX/CAPOX) before surgery for locally advanced colon (cT3-4 N0-2). Shows pathologic downstaging, higher R0, potential organ preservation. Not yet global standard but rapidly evolving.

1. Organ Preservation in Rectal Cancer (Watch & Wait): Expansion of criteria, better imaging (MRI TRG, Endoscopy), management of local regrowth (Salvage TME vs. Re-irradiation + Local Excision).
2. Immunotherapy Expansion:

• Neoadjuvant ICI (dMMR/MSI-H Rectal/Colon): NICHE, NEO-PRCR-C trials → Near 100% pCR / cCR rates. Potential to avoid Surgery AND Radiotherapy entirely in dMMR locally advanced disease. Practice-changing.
• MSS/pMMR CRC: Combination strategies (ICI + VEGF + Chemo, ICI + LAG-3, ICI + TIGIT, Oncolytic viruses) – Limited success so far (KEYNOTE-177 1st line metastatic only).

1. Targeted Therapy Advances:

• HER2: DESTINY-CRC02 (Trastuzumab Deruxtecan – ADC) – High response in HER2+ mCRC.
• KRAS G12C: Sotorasib/Adagrasib + Cetuximab/EGFRi (Combination overcoming feedback activation).
• Antibody-Drug Conjugates (ADCs): TROP2 (Sacituzumab Govitecan), CEACAM5, etc.

1. Artificial Intelligence (AI):

• CADe (Computer-Aided Detection): Real-time polyp detection during colonoscopy (↑ Adenoma Detection Rate – ADR).
• CADx (Characterization): Optical biopsy (predict histology, depth invasion).
• Pathology: Digital pathology algorithms for tumor budding, MSI prediction, grading standardization.

1. Microbiome Modulation: Fusobacterium nucleatum, pks+ E. coli (colibactin) linked to carcinogenesis. Trials of microbiome modulation (pre/pro/post-biotics, FMT) for prevention or enhancing immunotherapy efficacy.

11. Patient Information: Key Takeaways & Questions for Your Doctor

Key Takeaways

1. CRC is Preventable: Screening finds precancerous polyps before they become cancer. Start at 45 (average risk).
2. Early Detection = Cure: Stage I CRC has >90% 5-year survival. Symptoms often appear late.
3. Know Your Family History: It changes when and how often you screen. Tell your doctor about relatives with CRC or advanced polyps.
4. Molecular Testing is Standard: RAS, BRAF, MSI/MMR, HER2 results dictate exact drug choices in metastatic disease. Insist on the report.
5. Multidisciplinary Care is Essential: Surgeons, Medical Oncologists, Radiation Oncologists, Radiologists, Pathologists, Genetic Counselors, Stoma Nurses, Dietitians, Psychologists – all play a role.
6. Survivorship is a Phase of Care: Managing LARS, neuropathy, stoma, fear of recurrence, and cardiovascular health is part of oncology.

Questions to Ask Your Healthcare Team

• Diagnosis: “What is the exact stage? Has the tumor been tested for MMR/MSI, RAS, BRAF, and HER2?”
• Surgery: “Will I need a stoma (bag)? Temporary or permanent? What is the surgeon’s volume/experience with this specific cancer (CME/TME)?”
• Treatment: “Do I need chemotherapy/radiation? Why? What are the specific side effects (neuropathy, hand-foot syndrome, fatigue)? How long?”
• Clinical Trials: “Is there a clinical trial appropriate for my molecular subtype/stage?”
• Genetics: “Should I see a genetic counselor? Does my family need testing?”
• Surveillance: “What is my follow-up schedule for CT scans, CEA, and Colonoscopy?”
• Quality of Life: “Who do I talk to about bowel changes, sexual function, fatigue, or financial concerns?”

References

1. AJCC Cancer Staging Manual. 8th ed. Amin MB, Edge SB, Greene FL, et al., eds. Chicago, IL: American College of Surgeons; 2017.
2. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683-691. doi:10.1136/gutjnl-2015-310912
3. Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2024. J Natl Compr Canc Netw. 2024;22(5):378-386. doi:10.6004/jnccn.2024.0026
4. Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(6):452-460. doi:10.6004/jnccn.2024.0030
5. Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. 5th ed. Lyon: International Agency for Research on Cancer; 2019. (WHO Classification of Tumours Series, Vol. 1).
6. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834
7. Cercek A, Lumish M, Sinopoli J, et al. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022;386(25):2363-2376. doi:10.1056/NEJMoa2201445
8. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467-1480. doi:10.1016/S0140-6736(19)32319-0
9. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767. doi:10.1016/0092-8674(90)90186-i
10. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-1356. doi:10.1038/nm.3967
11. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology. 2010;138(6):2044-2058. doi:10.1053/j.gastro.2010.01.054
12. Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi64-72. (Updated in subsequent ESMO guidelines 2020/2023).
13. Loree JM, Kopetz S. The evolving landscape of metastatic colorectal cancer. Nat Rev Clin Oncol. 2023;20(10):651-668. doi:10.1038/s41571-023-00795-6
14. Meyerhardt JA, Mangu PB, Flynn PJ, et al. Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2013;31(33):4465-4470. (Updated: J Clin Oncol. 2022;40(26):3035-3046).
15. Naguib A, Wunsch K, Roesch T, et al. ctDNA-Guided Adjuvant Therapy in Stage II Colon Cancer: The DYNAMIC Trial. N Engl J Med. 2022;387(14):1252-1261. doi:10.1056/NEJMoa2206350
16. Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer. J Clin Oncol. 2018;36(8):773-779. doi:10.1200/JCO.2017.76.9901
17. Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015;148(1):77-87.e2. doi:10.1053/j.gastro.2014.09.045
18. Rex DK, Boland CR, Dominitz JA, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017;112(7):1016-1030. (Updated 2022/2023 guidance).
19. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219-3226. doi:10.1200/JCO.2009.27.1825
20. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Clinical Practice Guidelines: Colorectal cancer. Ann Oncol. 2023;34(10):946-964. doi:10.1016/j.annonc.2023.07.006
21. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145-164. doi:10.3322/caac.21601
22. Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 2019;5(12):1710-1717. doi:10.1001/jamaoncol.2019.2436
23. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386-1422. doi:10.1093/annonc/mdw235
24. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329(27):1977-1981. doi:10.1056/NEJM199312303292701
25. Yao Y, Li J, Huang H, et al. The prognostic value of tumor budding in colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2021;36(12):2557-2571. doi:10.1007/s00384-021-04022-3